Program:
Congestive heart failure (CHF), one of the leading manifestations of
cardiovascular disease, continues to be a major cause of morbidity and
mortality. The incidence of CHF can only be expected to increase as a
result of the aging of the population. Therapeutic advances based on new
beta-blockers and dual activity ACE inhibitors, endothelin antagonists, and
drugs targeting other novel mechanisms will be presented. Diagnostics and
new methods for evaluating the effectiveness of pharmaceuticals are being
developed for this indication.
Registration :
Cambridge Healthtech Institute
1037 Chestnut Street, Newton Upper Falls, MA 02164
Tel: 617-630-1300 Fax: 617-630-1325
E-Mail: chi@healthtech.com
Deadline for Abstracts: Dec. 12, 1997
Email for Requests and Registration: chi@healthtech.com